2023 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-05-12
±³À°ÀÏÀÚ : 2023-05-12
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼¿ï
±³À°ÁÖÁ¦ : 2023 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ
´ã´çÀÚ : Á¤ÃáÈñ
¿¬¶ôó : 02-747-0528
À̸ÞÀÏ : kaaaci@naver.com
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀÎ : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 19 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ, ÀϹÝÀÇ, ±³¼ö 8¸¸¿ø, Àü°øÀÇ, ±âŸ 4¸¸¿ø / ´çÀϵî·Ï: Àü¹®ÀÇ, ÀϹÝÀÇ, ±³¼ö 10¸¸¿ø, Àü°øÀÇ, ±âŸ 5¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 07:30~08:30 Exercise-Induced Asthma Stefano R. Del Giacco(University of Cagliari, Italy)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëD 07:30~08:30 Allergen Immunotherapy for Allergic Rhinitis Lei Cheng(Nanjing Medical University, China)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëE 07:30~08:30 SPT versus Phadiatop as a Tool for Diagnosis of Allergy Wasu Kamchisatian(Mahidol University, Thailand)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 08:30~09:00 Break ( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 09:00~10:00 Updates on Predictive Biomarkers and Novel Strategies of Immunotherapy Mohamed Shamji(Imperial College London, UK)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 10:00~10:10 Break ( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 10:10~10:40 Type 2 Inflammatory Diseases in the Upper Airway Tsuguhisa Nakayama( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 10:40~11:10 Phenotype and Endotype: Which Is a Better Approach to Treat AR and CRS ±è´ë¿ì(¼¿ïº¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 11:10~11:40 Impact of COVID-19 on AR and CRS Lei Cheng( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 10:10~10:40 How does Asthma Begin? Can We Prevent It? ¼Õ¸íÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 10:40~11:10 Asthma Inception: Infectious Agents and Antibiotics Interplay ±èÈ¿ºó(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 11:10~11:40 Vitamins, Metabolites and Asthma Inception ¾È°¸ð(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 11:40~11:50 Break ( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 11:50~12:50 Skin Test Based Strategy for Selecting Alternative Iodinated Contrast Media in Patients with Hypersensitivity Reaction: A Prospective Confirmative Study ÀÌÁöÇâ ¿Ü 5¸í(¿ï»êÀÇ´ë ¿Ü 5°÷)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 11:50~12:50 Severe asthma is associated with adverse COVID-19 outcomes ÀÌ¿ëö ¿Ü 5¸í(ÀüºÏÀÇ´ë ¿Ü 5°÷)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëD 11:50~12:50 Accuracy of skin tests in diagnosing cefaclor-induced immediate hypersensitivity reaction ½É´Ù¿î ¿Ü 5¸í(Àü³²ÀÇ´ë ¿Ü 5°÷)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëE 11:50~12:50 Gut microbiome changes following GLP-1 receptor agonist or probiotics treatment in a mouse model of obese asthma ÀÌÈ¿µ ¿Ü 5¸í(°¡Å縯ÀÇ´ë ¿Ü 5°÷)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 12:50~13:00 Break ( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 13:30~13:50 Advances in CSU Treatment Optimization: Yesterday, Today, and Tomorrow Marcus Maurer(Charité – Universitätsmedizin Berlin, Germany)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 13:30~13:50 Expanding Horizons: Targeting Type 2 Inflammation with Dupilumab as a Promising Therapeutic Strategy ¹ÚÈï¿ì(¼¿ïÀÇ´ë)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 13:50~14:00 Break ( )
Åä·Ð 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 14:00~14:30 Poster Discussion 1 ±èŹü ¿Ü 3¸í(¿ï»êÀÇ´ë ¿Ü 3°÷)
Åä·Ð 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 14:00~14:30 Poster Discussion 2 ±è»óÈÆ ¿Ü 3¸í(À»ÁöÀÇ´ë ¿Ü 3°÷)
Åä·Ð 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëD 14:00~14:30 Poster Discussion 3 ±è¿ì°æ ¿Ü 3¸í(ÀÎÁ¦ÀÇ´ë ¿Ü 3°÷)
Åä·Ð 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëE 14:00~14:30 Poster Discussion 4 ±è»óÇå ¿Ü 3¸í(ÇѾçÀÇ´ë ¿Ü 3°÷)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 14:30~14:40 Break ( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 14:40~15:40 Personalized Approach for Unmet Needs through Food Allergy Management Motohiro Ebisawa(Sagamihara National Hospital, Japan)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 15:40~15:50 Break ( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 15:50~16:40 Pros and Cons I. Is Premedication Needed for the Prevention of Radiocontrast Immediate Hypersensitivity? ¹Ú¼Ò¿µ, °¼ºÀ±(Áß¾ÓÀÇ´ë, °¡ÃµÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 15:50~16:40 Pros and Cons II. Does Maintenance Treatment with Inhaled Corticosteroids Affect Outcomes in Preterm-Born Children with Reduced Lung Function? ±è¼Ò¿¬, ±è°æÈÆ(¿¬¼¼ÀÇ´ë, ¼¿ïÀÇ´ë)
ÈÞ½Ä 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 16:40~17:00 Break ( )
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 17:00~17:30 How to Diagnose a Food Allergy Motohiro Ebisawa(Sagamihara National Hospital, Japan)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 17:30~18:00 How to Control Side Effects during Food Oral Immunotherapy? Á¤°æ¿í(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 18:00~18:30 Adult-Onset Food Allergy ½É´Ù¿î(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 17:00~17:30 Epidemiologic and Clinical Features of EGIDs in Adults ±è°¡Èñ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 17:30~18:00 Role of Allergy in EGIDs À̼¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 12ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 18:00~18:30 Updates of EGIDs in Children À̰ǼÛ(´Ü±¹ÀÇ´ë)